Sheller in Forbes.com “Will A Court Ruling Usher In Off-Label Promotions?”
2012-12-31 [pdf-embedder url=”http://sheller.com/wp-content/uploads/2015/07/SH_Forbes_Quote_SAS_12_12.pdf”] A U.S. Appeals Court ruling that pitted free speech rights versus off-label promotion of pharmaceuticals has raised speculation that 2013 may usher in the sort of aggressive marketing by drug makers that has previously drawn the wrath of federal prosecutors.
Sheller Risperdal settlements front page Legal Intelligencer
2012-10-05 The first trial in which evidence was taken in the mass tort litigation over Risperdal, the antipsychotic drug that plaintiffs have claimed causes males to grow breasts, was settled as part of a group of five cases that resolved this week for undisclosed amounts, according to the plaintiffs’ lawyers and a statement from the […]
J&J agrees to settle five Risperdal suits
2012-10-04 Sheller attorneys announce that five Risperdal cases have been settled for confidential amounts. “Our clients are very pleased,” Steve Sheller, a plaintiffs’ attorney, said in a Bloomberg report after the settlement was announced. “I’ll never be truly satisfied because of what happened here with these kids. It’s a sad commentary on what goes on […]
Sheller Client’s Mother Asks Judge in Risperdal Trial to Release J&J Report for Jurors
Philadelphia Inquirer 2012-09-28 Public companies file documents with the U.S. Securities and Exchange Commission all the time, and the chief executive officer signs them to say they are true. Shareholders and others can look at the statements at sec.gov. But showing particular documents to a jury is not so automatic. On Thursday, attorneys representing a […]
J&J Settles with Sheller client on first day of Risperdal jury trial
Bloomberg BusinessWeek 2012-09-10 – Johnson & Johnson (JNJ) settled a lawsuit on the first day of a trial over claims its antipsychotic drug Risperdal caused a male plaintiff to grow breast tissue, one of his lawyers told a state judge in Philadelphia. Visit this page for up to date national and regional news coverage on Sheller, P.C.’s representation […]
Sheller profiled in Suburban Life magazine
2012-07-02 – “Fighting for What’s Right”Stephen Sheller decided more than three decades ago to be a champion for people who have been hurt, victimized or otherwise had their rights trampled upon. His dedication to this cause has only intensified over time, recruiting others to join him in the fight. Click on icon to see the […]
Sheller quoted by Pharma Gossip Blog on Off-Label Marketing of Drugs
Pharma Gossip Blog/The Philadelphia Inquirer 2012-06-14 – “The problem with sentencing a corporation is that is has no soul to damn nor body to kick” ~ U.S. District Judge Douglas P. Woodlock referencing a 19th century British judge In a society that keeps score, the U.S. record for the largest financial penalty paid by a pharmaceutical company for […]
Jamie Sheller Speaks at Annual NetDiligence Cyber Risk and Privacy Liability Forum
2012-06-05 – Again this year, Jamie Sheller was a speaker at the Annual HB Litigation Conference NetDiligence Cyber Risk & Privacy Liability Forum. The forum took place June 4 and 5, 2012 at the Hyatt at the Bellevue, Philadelphia, PA. Attorney Sheller is on the panel “State of the Cyber National – Cases, Theories and […]
Jamie Sheller presents at PBI “How to Properly Document Settlement Agreements”
Continuing Legal Education Programs 2012-05-22 – Attorney Jamie Sheller presented at the May Pennsylvania Bar Institute continuing legal education program “How to Properly Document a Settlement Agreement: After the New Joint and Several Liability Law” in both Philadelphia May 15 and on May 22 in Mechanicsburg and by live simulcast to the Bucks County Bar Association […]
Sheller on Insider Exclusive “Deadly Drugs: Johnson & Johnson’s Risperdal”
Insider Exclusive Television Documentaries 2012-05-18 “Deadly Drugs: Johnson and Johnson’s Risperdal” examines the evolution of the drug Risperdal® from treatment of schizophrenia and extreme bipolar mania to off-label use in children and the elderly for behavior issues, sleep problems, and other uses, some which later became approved by the FDA. What is the cautionary tale? […]
